Interview with Michele Garot, Vice President, BeCRO
What was the motivation behind the establishment of BeCRO and why was it only established in 2010 given the strength of Belgium’s clinical trials industry? Philippe van der Hofstadt: Prior…
Address: Sint lambertusstraat 141 Rue Saint LambertB- 1200 Brussels,Belgium
Tel:
Web: http://www.becro.be/
BeCRO is the Belgian Association of CRO’s. BeCRO was initially founded by 19 member companies and has now grown to include 32 active members, representing more than a third of the 83 identified CRO’s in the country in 2011.
The aims of BeCRO are:
– To establish an association of service and consultancy companies active in pharmaceutical and medical development for health products, companies involved in the running of complete preclinical or clinical trials or parts thereof,- To represent and defend the interests of such companies to health authorities, companies, institutions and organisations operating in the health sector,- To be recognised as a privileged interlocutor by health authorities, any professional bodies and any national or international association and/or federation,- To establish good operating practices, with respect as regards highest quality rules and Good Clinical Practices,- To work towards training its members,- To promote the association.
What was the motivation behind the establishment of BeCRO and why was it only established in 2010 given the strength of Belgium’s clinical trials industry? Philippe van der Hofstadt: Prior…
Vanja Hoeben oversees the Benelux cluster for South Africa-headquartered specialty and branded pharma firm Aspen. He describes the reorganisation that his organisation has undergone in the past few years, some…
Maria Fernanda Prado highlights some of the lessons drawn from her extensive experience in emerging markets which remain applicable in her current role as Janssen’s managing director for the Benelux…
Japanese-headquartered Takeda has been undergoing a transformation in recent years, becoming the global leader in rare diseases with the acquisition of Shire in 2018 and divesting ‘non-core’ assets in OTC…
Werner De Prins oversees Bayer’s operations in Benelux, a significant region for the global group with over 2000 employees, a turnover of around EUR 1.2 billion and 10 different sites…
Stefan Joris of the Belgian Cystic Fibrosis Association (BCFA) highlights the progress that has been made on cystic fibrosis screening of newborns and reimbursement of innovative modulator therapies in Belgium…
Dr Frank Nobels, one of Belgium’s leading endocrinologists and diabetologists, introduces the Belgian Diabetes Forum – a multi-stakeholder initiative which aims to create efficient policy engagement in diabetes and make…
With two in-house Clinical Research Units (PCRUs), Pfizer uniquely keeps its phase I research within the company. As Medical/Scientific advisor at the Brussels PCRU and with a history of more…
After almost 20 years with AbbVie, Renaud Decroix still feels as engaged and motivated as ever by the goal of having a remarkable impact on patients’ lives. Decroix highlights some…
Medaxes – the Belgian industry association for companies producing generic and biosimilar medicines, as well as other off-patent medicines and self-care products – welcomed a new CEO in 2022, Jasmien…
Théa veteran and GM of the French ophthalmology midcap’s BeLux affiliate, Ivan Perrichon, reveals the company’s plans to pursue its growth trajectory, launch ten new products in Belgium and reach…
Belgium is a hugely significant country for GSK – which employs 9,000 people in the country – as host to three of the firm’s major vaccine sites, the global headquarters…
Paul Newton of Vertex Pharmaceuticals – one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry – outlines the company’s footprint…
See our Cookie Privacy Policy Here
